INmune Bio Inc. (INMB) shares rose 5.19% in after-hours on Friday, November 05, 2021, and closed the weekly trading at $15.01. However, in the regular trading session, INMB’s stock lost 19.06%. INMB shares have risen 68.88% over the last 12 months, and they have moved down 22.40% in the past week. Over the past three months, the stock has lost 9.28%, while over the past six months, it has jumped 38.54%.
Let’s discuss its recent news.
INMB latest announcement
On November 03, 2021, INmune Bio, Inc. (INMB) announced its financial results for the third quarter ended September 30, 2021.
Q3 2021 financial highlights
- Research and development expenses were $6.5 million in Q2 2021 compared to approximately $2.4 million in Q2 2020.
- General and administrative expenses were $2.5 million for the quarter ended September 30, 2021, compared to approximately $2.5 million during the quarter ended September 30, 2020.
- It suffered a net loss of approximately $9.5 million, compared to approximately $4.7 million for the quarter ended September 30, 2020.
- The company ended the quarter with $84.5 million in cash and cash equivalents.
INMB participation at the upcoming CTAD meeting
INmune Bio, Inc. (INMB) announced multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, being held in a hybrid format from November 9-12 in Boston.
INMB improved RS Rating
On September 22, 2021, Immune Bio (INMB) Relative Strength Rating jumped into the 90-plus percentile with an improvement to 92, up from 85.
INMB participation at the recent events
- INmune Bio, Inc. recently participated in an oncology panel at the B. Riley Fall 2021 Best Ideas in Oncology Series which was held on September 30, 2021. The company was presented by Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer during the event.
- INMB also participated at Cantor Fitzgerald Global Healthcare Conference which was held on Wednesday, September 29, 2021.
- The company also took part in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which was held on Wednesday, September 22, 2021.
Recent findings of INMB’s DN-TNF
On September 1, 2021, INmune Bio, Inc. (INMB)’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease (AD), treatment-resistant depression, and other neurological diseases where neuroinflammation is implicated was found to decrease multiple species of Phospho Tau (pTau) and improve neuroimaging biomarkers of myelination in patients with AD.
Conclusion
Well, we have no reason to justify its early loss and later recovery on Friday. let’s see how its resume trading on Monday after the weekend.
